These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37300636)

  • 1. Developing an Artificial Intelligence-Guided Signal Detection in the Food and Drug Administration Adverse Event Reporting System (FAERS): A Proof-of-Concept Study Using Galcanezumab and Simulated Data.
    Al-Azzawi F; Mahmoud I; Haguinet F; Bate A; Sessa M
    Drug Saf; 2023 Aug; 46(8):743-751. PubMed ID: 37300636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing Matters: A Machine Learning Method for the Prioritization of Drug-Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.
    Battini V; Cocco M; Barbieri MA; Powell G; Carnovale C; Clementi E; Bate A; Sessa M
    Drug Saf; 2024 Sep; 47(9):895-907. PubMed ID: 38687463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
    Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
    Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
    Dong G; Bate A; Haguinet F; Westman G; Dürlich L; Hviid A; Sessa M
    Drug Saf; 2024 Feb; 47(2):173-182. PubMed ID: 38062261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
    Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
    Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
    Sessa M; Andersen M
    BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-marketing safety surveillance of erenumab: new insight from Eudravigilance.
    Liang D; Sessa M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1205-1210. PubMed ID: 35236231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
    Michel C; Scosyrev E; Petrin M; Schmouder R
    Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
    Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA.
    Fukazawa C; Hinomura Y; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1402-1408. PubMed ID: 30324671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project.
    de Bie S; Ferrajolo C; Straus SM; Verhamme KM; Bonhoeffer J; Wong IC; Sturkenboom MC;
    PLoS One; 2015; 10(6):e0130399. PubMed ID: 26090678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions.
    Lu Z; Suzuki A; Wang D
    BMC Med Res Methodol; 2023 Mar; 23(1):71. PubMed ID: 36973693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.